Fly News Breaks for May 23, 2018
CARA
May 23, 2018 | 11:13 EDT
After Cara Therapeutics (CARA) announced a licensing arrangement with a joint venture between Vifor Pharma and Fresenius (FMS) for commercialization rights of IV-CR845 outside of the U.S., Japan and South Korea, Stifel analyst Annabel Samimy said he sees the deal offering a rapid go-to-market strategy with a readily accessible population at launch. He raised his price target on Cara shares to $20 and keeps a Buy rating on the stock following the licensing announcement.
News For CARA From the Last 2 Days
There are no results for your query CARA